Phase 3 Readout~month

Phase 3 Topline: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Daily Pi

Name: Phase 3 Topline: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Daily Pi
Start: 2028-06-01

June 1, 2028

Company: Can-Fite BioPharma Ltd. (CANF)
Drug: daily
Indication: Plaque Psoriasis

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start Free Full Calendar

Phase 3 Topline: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Daily Pi — CANF Phase 3 Readout | BioSniper